Details for Patent: 10,117,844

Which drugs does patent 10,117,844 protect, and when does it expire?

Patent 10,117,844 protects EPANOVA and is included in one NDA.

This patent has fifty-four patent family members in thirty-five countries.

Summary for Patent: 10,117,844

Title:	DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Abstract:	DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.
Inventor(s):	Maines; Timothy J. (Potomac, MD), Machielse; Bernardus N. (North Potomac, MD), Mehta; Bharat M. (Mendham, NJ), Wisler; Gerald L. (Windermere, FL), Davidson; Michael H. (Highland Park, IL), Wood; Peter Ralph (Glen View, GB)
Assignee:	Omthera Pharmaceuticals, Inc. (Princeton, NJ) Chrysalis Pharma AG (CH)
Application Number:	14/699,556
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 10,117,844

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca	EPANOVA	omega-3-carboxylic acids	CAPSULE;ORAL	205060-001	May 5, 2014		DISCN	Yes	No						TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET

International Family Members for US Patent 10,117,844

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013201793
Brazil	112014016788
Canada	2860512
Chile	2014001803
China	104321055